JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Enrique
Grande Pulido
Publicaciones en las que colabora con Enrique Grande Pulido (19)
2024
-
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
European Urology Open Science
2022
-
Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
Critical Reviews in Oncology/Hematology, Vol. 174
2021
2019
-
Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the Spanish 'Grupo Centro' of Genitourinary Tumors
Kidney Cancer, Vol. 3, Núm. 3, pp. 177-182
-
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
Cancer, Vol. 125, Núm. 8, pp. 1301-1312
-
Real-world outcome of 173 metastatic non-clear cell renal cell carcinoma (nccrcc) cases: The experience of the center group for genitourinary tumors
Kidney Cancer, Vol. 3, Núm. 1, pp. 41-50
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32
2017
-
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study
Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9
-
Docetaxel in prostate cancer: A familiar face as the new standard in a hormone-sensitive setting
Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 5, pp. 307-318
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190
2016
-
Controversies in the treatment of metastatic kidney cancer: A case report and review of the literature
Cancer and Chemotherapy Reviews, Vol. 11, Núm. 1, pp. 3-11
-
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations
Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141
-
Retrospective analysis of metastatic non-clear cell renal carcinoma (NCCRC): the Spanish Grupo Centro Experience
Annals of Oncology, Vol. 27, pp. vi290
2015
-
New advances in genitourinary cancer: evidence gathered in 2014
Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 443-464
2014
2005
-
Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
Clinical Breast Cancer, Vol. 6, Núm. 4, pp. 325-329